JTJulie-Anne Tanner

Julie-Anne Tanner

*This is an algorithmically generated author record based on publicly available information.

Julie-Anne Tanner has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmacogenomic Testing to Inform Prescribing in Patients with Behavioral and Psychiatric Symptoms of Dementia (BPSD): Results from Two Small, Randomized, Controlled Trials

    by Rachel Daut, Kunbo Yu, James Li, Lindsey Burns, Krystal Brown, Mark Pollack, Julie-Anne Tanner, David Geldmacher, Giovanna Pilonieta, Allan Anderson


  • Open Access

    Cost–Effectiveness of Combinatorial Pharmacogenomic Testing for Depression from the Canadian Public Payer Perspective

    by Julie-Anne Tanner, Paige E Davies, Christopher C Overall, Daniel Grima, Julian Nam, Bryan M Dechairo

    Aim: Evaluate cost–effectiveness of combinatorial pharmacogenomic (PGx) testing, versus treatment as usual (TAU), to guide treatment for patients with depression, from the Canadian public healthcar...


  • Economic Burden of Depression and Associated Resource Use in Manitoba, Canada

    by Julie-Anne Tanner, Jennifer Hensel, Paige E. Davies, Lisa C. Brown, Bryan M. Dechairo, Benoit H. Mulsant

    Objectives: To characterize the health-care utilization and economic burden associated with depression in Manitoba, Canada. Methods: Patient-level data were retrieved from the Manitoba Centre for Health Policy administrative, clinical, and laboratory databases for the study period of January 1, 1996, through December 31, 2016. Patients were assigned to the depression cohort based on diagnoses recorded in hospitalizations and outpatient physician claims, as well as antidepressant prescription drug claims. A comparison cohort of nondepressed subjects, matched with replacement for age, gender, place of residence (urban vs. rural), and index date, was created. Demographics, comorbidities, intentional self-harm, mortality, health-care utilization, prescription drug utilization, and costs of health-care utilization and social services were compared between depressed patients and matched nondepressed patients, and incidence rate ratios and hazard ratios were reported. Results: There were 190,065 patients in the depression cohort and 378,177 patients in the nondepression cohort. Comorbidities were 43% more prevalent among depressed patients. Intentional self-harm, all-cause mortality, and suicide mortality were higher among patients with depression than the nondepression cohort. Health-care utilization—including hospitalizations, physician visits, physician-provided psychotherapy, and prescription drugs—was higher in the depression than the nondepression cohort. Mean health-care utilization costs were 3.5 times higher among depressed patients than nondepressed patients ($10,064 and $2,832, respectively). Similarly, mean social services costs were 3 times higher ($1,522 and $510, respectively). Overall, depression adds a total average cost of $8,244 ( SD = $40,542) per person per year. Conclusions: Depression contributes significantly to health burden and per patient costs in Manitoba, Canada. Extrapolation of the results to the entire Canadian health-care system projects an excess of $12 billion annually in health system spending.


  • Open Access

    Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications

    by Julie-Anne Tanner, Lisa C Brown, Kunbo Yu, James Li, Bryan M Dechairo

    Objective: To estimate Canadian pharmacy cost savings associated with psychiatric medication prescribing that is guided by combinatorial pharmacogenomic testing in patients switching or augmenting their psychiatric medication. Methods: Pharmacy claims data from a United States (US) pharmacy benefit manager were analyzed for 1662 patients who recently augmented or switched to a different antidepressant or antipsychotic medication and underwent combinatorial pharmacogenomic testing. Costs of prescription medications were translated to the Canadian healthcare system by matching drug names and doses using the Ontario Drug Benefit Formulary. One-year costs (2017 CAD) were compared between patients whose clinician prescribed antidepressants or antipsychotics that were consistent (congruent) or inconsistent (incongruent) with the combinatorial pharmacogenomic test recommendations. Results: Patients whose psychiatric medication treatment was congruent with the combinatorial pharmacogenomic test report saved $1061 CAD per member per year (PMPY) on prescription medication costs relative to patients whose medications were incongruent with their test report (pConclusions: Antidepressant and antipsychotic prescribing that was congruent with combinatorial pharmacogenomic test guidance was associated with significant cost savings on Canadian prescription medications according to the Ontario Drug Benefit Formulary.